“We are at a crucial moment in our fight against cancer,” said ESMO President Prof. Jose Baselga. “We have never before made so much progress in our fight to eradicate cancer as a cause of death, and multidisciplinary treatment is a key factor in this success.”
New data presented at the 33rd ESMO Congress, 12-16 September 2008, Stockholm, Sweden also highlight the benefits of combined treatments:
Phase II trial of pazopanib before surgery in early lung cancer
Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report. In a phase II trial, 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumor size shrink by up to 85%.
“This is a positive result that will be explored further,” said Prof. Nasser Altorki from Weil Medical College of Cornell University in New York. “To my knowledge, no other results on the effect of angiogenesis inhibitors in early stage operable lung cancer have been published. The results presented here with pazopanib indicate a highly active drug in this setting and further development in lung cancer is underway to fully understand the value of this drug in this disease.”
Chemotherapy, radiotherapy and cetuximab in head and neck cancer
Treating locally advanced head and neck cancers with an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, has shown promise in a phase II trial, Italian researchers report.
Their trial in 45 patients combined chemotherapy with fluorouracil and carboplatin given on weeks 1, 4 and 7 of treatment, with radiotherapy administered daily on weeks 2-3, 5-6 and 8-10. Cetuximab was also added weekly. “Both complete response rate and long-term results compare favorably with the best reported in the literature,” Dr. Marco Merlano from the S. Croce General Hospital in Cuneo reports. 30 patients experienced a skin toxicity that the authors attribute to an interaction between the treatments, and 2 patients died from toxicities, they report.
Zoledronic acid added to adjuvant endocrine therapy prevents breast cancer recurrences
One-third of breast cancer recurrences in pre-menopausal women can be prevented by adding zoldronic acid to treatment with endocrine therapy combined with anastrazole or tamoxifen.
These results, reported for the first time recently, show that “we can positively impact the fate of our cancer patients by influencing the microenvironment of micro-metastases by relatively simple means,” says lead author Prof. Michael Gnant from the Medical University of Vienna.
The study results are included in the ESMO "Oncology Highlights" session in Stockholm. The findings will be expanded with new data from a multivariate analysis of the variables affecting disease-free and recurrence-free survival, Professor Gnant said.
Vanessa Pavinato | alfa
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy